Please replace the present set of claims with the following amended claims.

1. (Withdrawn) A monoclonal antibody for detecting urinary trypsin inhibitors (UTI) in the biological fluids of persons having disease, said antibody being secreted by a hybridoma produced from purified uristatin.

2. (Canceled)

3. (Withdrawn) A monoclonal antibody of Claim 1, said antibody being secreted by hybridoma ATCC421-5G8.1A8.5C1.

4. (Withdrawn) A monoclonal antibody of Claim 3, wherein uristatin and uristatin-1 and-2 are strongly detected.

5. (Withdrawn) A monoclonal antibody of Claim 1, said antibody being secreted by hybridoma ATCC420-5D11. 5G8. 1E4.

6. (Withdrawn) A monoclonal antibody of Claim 5, wherein uristatin and uristatin-1 and -2 are strongly detected and said monoclonal antibody further binds strongly to Tamm-Horsfall protein (THP).

7. (Withdrawn) A monoclonal antibody of Claim 1, said antibody being secreted by hybridoma ATCC 421-3G5.4C5. 3B6.

8. (Withdrawn) A monoclonal antibody of Claim 7, wherein uristatin, uristatin-1 and -2, bikunin and AMBK are strongly detected.

9. (Withdrawn) A monoclonal antibody of any one of Claims 1 and 3-8 for detecting UTI in blood or urine.

10. (Withdrawn) A monoclonal antibody of Claims 3 or 7 for detecting UTI in urine.

11. (Withdrawn) A monoclonal antibody of Claim 5 for detecting UTI in blood plasma.

12. (Currently Amended) A method of assaying a biological fluid for urinary trypsin inhibitors (UTI) comprising contacting a sample of biological fluid with a monoclonal antibody secreted by a hybridoma produced from purified uristatin and identifying UTIs preferentially bound by said monoclonal antibody, said monoclonal antibody having no cross-reactivity to P- α-I and I- α-I pro-inhibitors.

13. (Canceled)

14. (Currently Amended) A method of Claim 12, wherein said monoclonal antibody is secreted by one of the group of hybridomas ATCC 421-5G8.1A8.5C1, ATCC 420-5D11.5G8.1E4, and ATCC 421-3G5.4C5.3B6 and identifying UTIs preferentially bound to said antibody.

15. (Currently Amended) A method of Claim 14, wherein said monoclonal antibody is secreted from hybridoma ATCC 421-5G8.1A8.5C1 and uristatin and uristatin-1 and -2 are ~~strongly detected~~ preferentially bound UTIs.

16. (Currently Amended) A method of Claim 14, wherein said monoclonal antibody is secreted from hybridoma ATCC 420-5D11.1E4 and uristatin and uristatin-1 and -2 are preferentially bound UTIs ~~strongly detected~~ and said monoclonal antibody further ~~binds strongly~~ preferentially binds to Tamm-Horsfall protein (THP).

17. (Currently Amended) A method of Claim 14, wherein said monoclonal antibody is secreted from hybridoma ATCC 421-3G5.4C5.3B6 and uristatin, uristatin-1 and 2, bikunin and AMBK are ~~strongly detected~~ preferentially bound UTIs.

18. (Previously Presented) A method of Claim 14 wherein said UTIs are identified in an immunoassay.

19. (Currently Amended) A method of Claim 18 wherein said immunoassay is selected from the group consisting of MIC, LAI, IC, RIA, ELISA, EIA, FIA, LIA, CLA, OA, EST and rare earth metals label assays, ~~as~~ said immunoassay acronyms defined herein.

20. (Previously Presented) A method of Claim 12 wherein said biological fluid is urine.

21. (Previously Presented) A method of Claim 12 wherein said biological fluid is blood plasma.

22. (Previously Presented) A method of Claim 20, wherein said antibody is secreted by the hybridoma ATCC 421-5G8.1A8.5C1 or hybridoma ATCC 421-3G5.4C5.3B6.

23. (Currently Amended) A method of Claim 21, wherein said antibody is secreted by the hybridoma ATCC 420-5D11.5G8 1E4.

24. (Canceled).

25. (Canceled).

26. (Currently Amended) A method of assaying a biological fluid for urinary trypsin inhibitors (UTI) comprising the steps of :

(a) adding a biological fluid sample suspected of containing urinary trypsin inhibitors to a substrate;

(b) adding to said sample of (a) monoclonal antibody secreted from a hybridoma selected from the group consisting of ATCC 421-5G8.1A8.5C1, ATCC 420-5D11.5G8.1E4, and ATCC 421-3G5.4C5.3B6, said antibody having no cross-reactivity to P- α-I and I- α-I pro-inhibitors;

(c) adding to the combined monoclonal antibodies of (b) and the biological sample of (a) a ligand capable of binding to said monoclonal antibodies, said ligands being bound to an enzyme;

(d) washing from the combined monoclonal antibody of (b), the biological sample of (a) and the ligand of (c) the portion of said ligand unbound to said monoclonal antibody;

(e) determining the amount of said urinary trypsin inhibitors bound to said monoclonal antibody and said ligands by adding a reporter molecule capable of developing a signal by reaction with said enzyme; and

(f) correlating the signal developed with the amount of said urinary trypsin inhibitors.

27. (Canceled).

28. (Canceled).

29. (Previously Presented) A method of Claim 26, wherein said biological sample is urine.

30. (Previously Presented) A method of Claim 29, wherein said antibody is secreted by the hybridoma ATCC 421-5G8.1A8.5C1 or hybridoma ATCC 421-3G5.4C5.3B6.

31. (Previously Presented) A method of Claim 26, wherein said biological sample is blood plasma.

32. (Previously Presented) A method of Claim 31 wherein said antibody is secreted by the hybridoma ATCC 420-5D11.5G8.1E4.

33. (New) A method of assaying a biological fluid for UTI comprising contacting a sample of biological fluid with a monoclonal antibody secreted by hybridoma ATCC 421-5G8.1A8.5C1 or hybridoma ATCC 421-3G5.4C5.3B6 and determining the relative amounts of uristatin, uristatin-1, and uristatin-2 in said sample, said monoclonal antibody being capable of detecting uristatin, uristatin-1, and uristatin-2 without cross reactivity to THP and the pro-inhibitors P- α -I and I- α –I.

34. (New) The method of Claim 33 wherein said biological fluid is urine.

35. (New) A method of assaying a biological fluid for UTI comprising contacting a sample of said biological fluid with a monoclonal antibody secreted by hybridoma ATCC 420-5D11.5G8.1E4 and determining the relative amounts of uristatin, uristatin-1, and uristatin-2 in said sample, said monoclonal antibody being capable of detecting uristatin, uristatin-1, and uristatin-2, and THP without cross-reactivity to the pro-inhibitors P- α -I and I- α –I.

36. (New) The method of Claim 35 wherein said biological fluid is blood plasma.